Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 357 results
Filters: Author is Acosta, Edward P  [Clear All Filters]
Found 357 results.

Adult

Acosta EP, Kendall MA, Gerber JG, et al. "Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily." Antimicrob. Agents Chemother.. 2007;51(9):3104-10.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)." HIV Clin Trials. 2009;10(6):343-55.
Haas DW, Kwara A, Richardson DM, et al. "Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes." J. Antimicrob. Chemother.. 2014;69(8):2175-82.
Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. "Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects." J. Infect. Dis.. 2008;197(6):867-70.
Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. "Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria." J Pharmacokinet Pharmacodyn. 2007;34(1):35-55.
Andrade A, Rosenkranz SL, Cillo AR, et al. "Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248." J. Infect. Dis.. 2013;208(6):884-91.
Ribaudo HJ, Kuritzkes DR, Lalama CM, et al. "Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts." J. Infect. Dis.. 2008;197(7):1006-10.
Ribaudo HJ, Haas DW, Tierney C, et al. "Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study." Clin. Infect. Dis.. 2006;42(3):401-7.
Gerber JG, Kitch DW, Fichtenbaum CJ, et al. "Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186." J. Acquir. Immune Defic. Syndr.. 2008;47(4):459-66.
Haas DW, Koletar SL, Laughlin L, et al. "Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir." J. Acquir. Immune Defic. Syndr.. 2009;50(3):290-3.
Gay CL, Bosch RJ, Ritz J, et al. "Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy." J. Infect. Dis.. 2017;215(11):1725-1733.
Riddler SA, Jiang H, Tenorio A, et al. "A randomized study of antiviral medication switch at lower- versus higher-switch thresholds: AIDS Clinical Trials Group Study A5115." Antivir. Ther. (Lond.). 2007;12(4):531-41.
Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. "Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission." J. Infect. Dis.. 2013;208(4):662-71.
Wanga V, Venuto C, Morse GD, et al. "Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202." Pharmacogenet. Genomics. 2015;25(9):450-61.
Gulick RM, Ribaudo HJ, Shikuma CM, et al. "Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial." JAMA. 2006;296(7):769-81.
Taiwo B, Zheng L, Gallien S, et al. "Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)." AIDS. 2011;25(17):2113-22.

Pages